TY  - JOUR
A1  - Pippias, Maria
A1  - Stel, Vianda S.
A1  - Diez, José Maria Abad
A1  - Afentakis, Nikolaos
A1  - Herrero-Calvo, Jose Antonio
A1  - Arias, Manuel
A1  - Tomilina, Natalia
A1  - Caamaño, Encarnación Bouzas
A1  - Buturovic-Ponikvar, Jadranka
A1  - Čala, Svjetlana
A1  - Caskey, Fergus J.
A1  - de la Nuez, Pablo Castro
A1  - Cernevskis, Harijs
A1  - Collart, Frederic
A1  - de la Torre, Ramón Alonso
A1  - de los Ángeles García Bazaga, Maria
A1  - De Meester, Johan
A1  - Díaz, Joan Manuel
A1  - Djukanovic, Ljubica
A1  - Alamar, Manuel Ferrer
A1  - Finne, Patrik
A1  - Garneata, Liliana
A1  - Golan, Eliezer
A1  - González Fernández, Raquel
A1  - Gutiérrez Avila, Gonzalo
A1  - Heaf, James
A1  - Hoitsma, Andries
A1  - Kantaria, Nino
A1  - Kolesnyk, Mykola
A1  - Kramar, Reinhard
A1  - Kramer, Anneke
A1  - Lassalle, Mathilde
A1  - Leivestad, Torbjørn
A1  - Lopot, Frantisek
A1  - Macário, Fernando
A1  - Magaz, Angela
A1  - Martín-Escobar, Eduardo
A1  - Metcalfe, Wendy
A1  - Noordzij, Marlies
A1  - Palsson, Runolfur
A1  - Pechter, Ülle
A1  - Prütz, Karl G.
A1  - Ratkovic, Marina
A1  - Resić, Halima
A1  - Rutkowski, Boleslaw
A1  - de Pablos, Carmen Santiuste
A1  - Spustová, Viera
A1  - Süleymanlar, Gültekin
A1  - Van Stralen, Karlijn
A1  - Thereska, Nestor
A1  - Wanner, Christoph
A1  - Jager, Kitty J.
T1  - Renal replacement therapy in Europe: a summary of the 2012 ERA-EDTA Registry Annual Report
JF  - Clinical Kidney Journal
N2  - Background
This article summarizes the 2012 European Renal Association—European Dialysis and Transplant Association Registry Annual Report (available at www.era-edta-reg.org) with a specific focus on older patients (defined as ≥65 years).

Methods
Data provided by 45 national or regional renal registries in 30 countries in Europe and bordering the Mediterranean Sea were used. Individual patient level data were received from 31 renal registries, whereas 14 renal registries contributed data in an aggregated form. The incidence, prevalence and survival probabilities of patients with end-stage renal disease (ESRD) receiving renal replacement therapy (RRT) and renal transplantation rates for 2012 are presented.

Results
In 2012, the overall unadjusted incidence rate of patients with ESRD receiving RRT was 109.6 per million population (pmp) (n = 69 035), ranging from 219.9 pmp in Portugal to 24.2 pmp in Montenegro. The proportion of incident patients ≥75 years varied from 15 to 44% between countries. The overall unadjusted prevalence on 31 December 2012 was 716.7 pmp (n = 451 270), ranging from 1670.2 pmp in Portugal to 146.7 pmp in the Ukraine. The proportion of prevalent patients ≥75 years varied from 11 to 32% between countries. The overall renal transplantation rate in 2012 was 28.3 pmp (n = 15 673), with the highest rate seen in the Spanish region of Catalonia. The proportion of patients ≥65 years receiving a transplant ranged from 0 to 35%. Five-year adjusted survival for all RRT patients was 59.7% (95% confidence interval, CI: 59.3–60.0) which fell to 39.3% (95% CI: 38.7–39.9) in patients 65–74 years and 21.3% (95% CI: 20.8–21.9) in patients ≥75 years.
KW  - end-stage renal disease
KW  - incidence
KW  - prevalence
KW  - renal replacement therapy
KW  - survival
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-150054
VL  - 8
IS  - 3
ER  - 
TY  - JOUR
A1  - Estes, Chris
A1  - Anstee, Quentin M.
A1  - Arias-Loste, Maria Teresa
A1  - Bantel, Heike
A1  - Bellentani, Stefano
A1  - Caballeria, Joan
A1  - Colombo, Massimo
A1  - Craxi, Antonio
A1  - Crespo, Javier
A1  - Day, Christopher P.
A1  - Eguchi, Yuichiro
A1  - Geier, Andreas
A1  - Kondili, Loreta A.
A1  - Kroy, Daniela C.
A1  - Lazarus, Jeffrey V.
A1  - Loomba, Rohit
A1  - Manns, Michael P.
A1  - Marchesini, Giulio
A1  - Nakajima, Atsushi
A1  - Negro, Francesco
A1  - Petta, Salvatore
A1  - Ratziu, Vlad
A1  - Romero-Gomez, Manuel
A1  - Sanyal, Arun
A1  - Schattenberg, Jörn M.
A1  - Tacke, Frank
A1  - Tanaka, Junko
A1  - Trautwein, Christian
A1  - Wei, Lai
A1  - Zeuzem, Stefan
A1  - Ravazi, Homie
T1  - Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
JF  - Journal of Hepatology
N2  - Background & Aims
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. This burden is expected to increase as epidemics of obesity, diabetes and metabolic syndrome continue to grow. The goal of this analysis was to use a Markov model to forecast NAFLD disease burden using currently available data.

Methods
A model was used to estimate NAFLD and NASH disease progression in eight countries based on data for adult prevalence of obesity and type 2 diabetes mellitus (DM). Published estimates and expert consensus were used to build and validate the model projections.

Results
If obesity and DM level off in the future, we project a modest growth in total NAFLD cases (0–30%), between 2016–2030, with the highest growth in China as a result of urbanization and the lowest growth in Japan as a result of a shrinking population. However, at the same time, NASH prevalence will increase 15–56%, while liver mortality and advanced liver disease will more than double as a result of an aging/increasing population.

Conclusions
NAFLD and NASH represent a large and growing public health problem and efforts to understand this epidemic and to mitigate the disease burden are needed. If obesity and DM continue to increase at current and historical rates, both NAFLD and NASH prevalence are expected to increase. Since both are reversible, public health campaigns to increase awareness and diagnosis, and to promote diet and exercise can help manage the growth in future disease burden.

Lay summary
Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis can lead to advanced liver disease. Both conditions are becoming increasingly prevalent as the epidemics of obesity and diabetes continue to increase. A mathematical model was built to understand how the disease burden associated with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis will change over time. Results suggest increasing cases of advanced liver disease and liver-related mortality in the coming years.
KW  - burden of disease
KW  - cardiovascular disease
KW  - health care resource utilization
KW  - metabolic syndrome
KW  - NAFLD
KW  - NASH
KW  - cirrhosis
KW  - HCC
KW  - diabetes mellitus
KW  - obesity
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-227286
VL  - 69
ER  -